ReviewAntibiotics (Basel, Switzerland)2025
Multidrug-Resistant
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Distribution of Non-Fermenting Gram-Negative Bacilli and Carbapenem Resistance Profiles in Intensive Care Units of a Foundation University Hospital: A 2023-2025 Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- In Vitro Synergistic Effects of Selected Essential Oil Components Against ClinicalMolecules (Basel, Switzerland) · 2026Article
- Beyond minimum inhibitory concentration values: clinical and diagnostic challenges of colistin heteroresistance in Acinetobacter baumannii.Molecular biology reports · 2026Review
- Antibiotic Resistance ofAnimals : an open access journal from MDPI · 2026Article
- Clinical Severity and Organ Dysfunction as Drivers of Mortality in Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- Six Years ofAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Efficacy and Safety of Different Colistin Administration Routes for Nosocomial Pneumonia Caused by Carbapenem-Resistant Organisms: A Single Centre, Open Label, Prospective Cohort Study [Letter].Drug design, development and therapy · 2026Article
- Resistome, virulome and genomic insights into the silent dissemination ofFrontiers in cellular and infection microbiology · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- Predictive Factors for Upper Urinary Tract Stones Combined with Carbapenem-Resistant Enterobacteriaceae Associated Urinary Tract Infections.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.